Compare XPON & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XPON | NXL |
|---|---|---|
| Founded | 2016 | 2010 |
| Country | United States | United States |
| Employees | N/A | 7 |
| Industry | Electronic Components | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8M | 8.3M |
| IPO Year | 2022 | N/A |
| Metric | XPON | NXL |
|---|---|---|
| Price | $0.66 | $0.36 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 205.9K | 101.7K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 94.63 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $9,651,870.00 | N/A |
| Revenue This Year | N/A | $120.99 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 71.59 | N/A |
| 52 Week Low | $0.49 | $0.34 |
| 52 Week High | $5.50 | $2.31 |
| Indicator | XPON | NXL |
|---|---|---|
| Relative Strength Index (RSI) | 51.29 | 34.89 |
| Support Level | $0.65 | N/A |
| Resistance Level | $0.68 | $0.46 |
| Average True Range (ATR) | 0.05 | 0.03 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 84.67 | 8.60 |
Expion360 Inc is focused on the design, assembly, manufacturing, and sales of lithium iron phosphate (LiFePO4) batteries and supporting accessories for recreational vehicles (RV's) and marine applications with plans to expand into home energy storage products and industrial applications. Its product offerings include some of the minimal-footprint batteries in the RV & Marine industry.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.